GI Innovation, Inc. (KOSDAQ:358570)

Market Cap	933.78B +40.6%
Revenue (ttm)	338.09M -92.9%
Net Income	-51.99B
EPS	-976.21
Shares Out	64.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	602,915
Average Volume	774,280
Open	14,700
Previous Close	14,620
Day's Range	14,460 - 15,500
52-Week Range	11,240 - 24,900
Beta	0.13
RSI	49.75
Earnings Date	n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 358570

Financial Performance

In 2024, GI Innovation's revenue was 24.28 million, a decrease of -99.54% compared to the previous year's 5.32 billion. Losses were -58.78 billion, 5.93% more than in 2023.